Delpor develops the next generation Drug Delivery Systems that improve the clinical and commercial value of drugs and biopharmaceuticals. The company also has developed a microfabricated nanopore device for the sustained release of therapeutic agents.
The company is focused on the use of fullerene carbon nanotubes for novel therapeutic applications specifically in the area of cancer treatment. The company's extensive carbon nanotube-related, worldwide intellectual property portfolio includes discoveries by the late Nobel Prize winner Dr Rick Smalley. The use of fullerene carbon nanotubes has the goal of solving two important problems for many cancer therapeutics, that of delivering large active agents into the desired location and of protecting normal tissue from the active agent during delivery.
The company develops unique molecular delivery systems. Its spherical micrometer sizes polymer particles act like micro sponges and absorb molecules while the sub-micrometer sized Hollow silica shells have an internal void space and act much like a standard container.
Keystone Nano has an exclusive license to Penn State patented technology that allows the creation of stable, non-toxic, 5 to 50 nm-composite particles that they call Molecular Dots (MDs). These Molecular Dots can encapsulate drugs and/or fluorescent molecules.
The combination of a protected blood transporting nanocarrier system and a tumor specific activation technology makes LiPlasome Pharma very competitive in a commercially attractive and dynamic anticancer market, where drug delivery systems will gain increasing importance over the coming years.
Living Cell is developing cell-based products to treat life threatening human diseases. The company has developed proprietary nanobiocapsules which allow encapsulated pig insulin producing cells, DiabeCell, to be implanted without the use of toxic immune suppressive drugs.
Makefield Therapeutics has licensed Intellectual Property covering a novel platform technology from Albert Einstein College of Medicine of Yeshiva University for the generation of powders comprised of hydrogel/glassy matrix (hybrid) nanoparticles that in a first application are delivering controlled and sustained therapeutic levels of gaseous nitric oxide
Nanocopoeia is a therapeutic particle engineering company providing nano-enabled particle design, services, and equipment to the pharmaceutical industry. Their patented ElectroNanospray™ (ENS) process is used to produce homogeneous nanoparticles in a unique one-step continuous process. They have the ability to engineer multicomponent particles. ENS is a non-destructive process operating at ambient temperature and pressure. The modular equipment design allows for easy entry at R&D scale moving to pilot and full scale production.
NanoMedical Systems (NMS) is a startup company, which will commercialize the patented research of Dr. Mauro Ferrari at the University of Texas Health Science Center in Houston, a sponsored research site and a source of licensed IP for NMS. The company's Personalized Molecular Drug-delivery System (PMDS) is a small drug delivery device that is implanted subcutaneously (just under the skin) for slow and consistent release of a therapeutic agent over many weeks or months. A nanochannel delivery system (nDS) embodied on a silicon chip regulates the flow of therapeutic molecules.
NanoStar Health aims to become a global leader in the emerging technology arena of nanomedical devices specifically designed for premature infants. The Company began operations in March 2009 and was incorporated in May 2009 to capitalize on the founder's expertise in nanotechnology, neonatal and pediatric medicine, and medical device commercialization.